MedPath

Amniotic Biomarkers for the Prediction of Postpartum Renal Function.

Completed
Conditions
Nephropathy
Registration Number
NCT02675686
Lead Sponsor
University Hospital, Toulouse
Brief Summary

The discovery of antenatal bilateral renal anomaly poses an essential question: can we predict postnatal renal function? Ultrasound is insufficiently precise to predict postnatal renal function evolution.

The objective of this study is to estimate the specificity and sensitivity of amniotic fluid biomarkers to predict postnatal renal function in fetuses with bilateral developmental nephropathies.

Both fetuses with bilateral renal anomalies and control (healthy) fetuses will be included.

For this study amniotic fluid will only be collected according to routine clinical practice and only excess amniotic fluid sample will be used for the study.

The potentially identified biomarkers will not change routine management of the pregnancies in the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
358
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Renal function (according to Schwartz formula)month 24

Renal function (according to Schwartz formula)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Hopital Nord

🇫🇷

St-priest-en-jarez, France

Chu D Angers

🇫🇷

Angers, France

Hopital Saint Jacques

🇫🇷

Besancon, France

Hopital Pellegrin

🇫🇷

Bordeaux, France

Hopital Morvan

🇫🇷

Brest, France

Hopital Femme-Mere-Enfant

🇫🇷

Bron, France

Ch Rene Dubos Pontoise

🇫🇷

Cergy Pontoise, France

Hopital Antoine Beclere (Ap Hp)

🇫🇷

Clamart, France

Chu Estaing

🇫🇷

Clermont Ferrand, France

Hopital Du Bocage

🇫🇷

Dijon, France

Scroll for more (20 remaining)
Hopital Nord
🇫🇷St-priest-en-jarez, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.